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Urea Uptake Enhances Barrier Function and
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Urea is an endogenous metabolite, known to enhance stratum corneum hydration. Yet, topical urea anecdotally
also improves permeability barrier function, and it appears to exhibit antimicrobial activity. Hence, we
hypothesized that urea is not merely a passive metabolite, but a small-molecule regulator of epidermal structure
and function. In 21 human volunteers, topical urea improved barrier function in parallel with enhanced
antimicrobial peptide (AMP; LL-37 and b-defensin-2) expression. Urea stimulates the expression of, and is
transported into, keratinocytes by two urea transporters (UTs), UT-A1 and UT-A2, and by aquaporins 3, 7, and 9.
Inhibitors of these UTs block the downstream biological effects of urea, which include increased mRNA and
protein levels of (i) transglutaminase-1, involucrin, loricrin, and filaggrin, (ii) epidermal lipid synthetic enzymes,
and (iii) cathelicidin/LL-37 and b-defensin-2. Finally, we explored the potential clinical utility of urea, showing
that topical urea applications normalized both barrier function and AMP expression in a murine model of atopic
dermatitis. Together, these results show that urea is a small-molecule regulator of epidermal permeability
barrier function and AMP expression after transporter uptake, followed by gene regulatory activity in normal
epidermis, with potential therapeutic applications in diseased skin.
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INTRODUCTION
Human epidermis is the most external tissue of the body,
serving at least three critical functions, i.e., provision of a
barrier against (i) transcutaneous water loss, (ii) penetration
of microbial pathogens, and (iii) ingress of potentially toxic
xenobiotics (Marks, 2004). These major barrier functions
localize to the outermost layer of the epidermis, i.e., the
stratum corneum, which consists of extracellular lipid-
enriched lipid lamellar bilayers enriched in ceramides,
cholesterol, and free fatty acids, surrounding anucleate
corneocytes, filled with filaggrin and its metabolites and
keratin filaments (Loden, 2005). Individual corneocytes are
surrounded by a unique cornified envelope composed of
proteins (e.g., involucrin and loricrin), which are cross-linked
into a rigid, mechanically resistant structure, by the calcium-
dependent enzyme, transglutaminase 1 (TG-1; Iismaa et al.,
2009).
During epidermal differentiation, keratinocytes progress
vertically from mitotically active basal cells into transcrip-
tionally active spinous and granular cells to flattened,
differentiated squames in the stratum corneum. This carefully
orchestrated program allows continuous epidermal regenera-
tion over a lifetime. Epidermal barrier function is regulated
by several small molecules, including lipid and hormonal
activators of nuclear hormone receptors, cytokines, and
divalent cations, particularly calcium (Proksch et al., 2008).
Although topical urea has been used for decades to enhance
hydration, as well as a keratolytic agent in psoriasis,
ichthyosis, and dermatophytosis (Loden, 2005; Scheinfeld,
2010), anecdotal reports also suggest that urea improves
barrier function after topical use, and that urea is beneficial
for cutaneous infectious diseases, such as onychomycosis.
Although it is widely assumed that urea acts solely by virtue
of its moisturizing capacity, all of these disorders are also
characterized by a perturbation of epidermal barrier function
and/or altered antimicrobial defense. These observations
together lead us to hypothesize that the beneficial effects
of urea extend beyond its passive role as a moisturizer or
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keratolytic agent, suggesting instead that urea could have
additional regulatory activities within the nucleated layers
of the epidermis, which could impact cutaneous barrier
function and/or antimicrobial defense.
In previous studies, we have shown that normal human
keratinocytes (NHK) possess an osmolyte strategy that
maintains cell volume as a part of their response to
exogenous perturbations, such as UV radiation (Warskulat
et al., 2004; Rockel et al., 2007). Urea is a non-toxic, water-
soluble carrier of excreted nitrogen, which can only be
further metabolized by urease-positive, micro-organisms
within the gut (Walser and Bodenlos, 1959). In many
extracutaneous cell types, exogenous urea is taken up by
specific urea transporters (UTs), UT-A and UT-B (Lucien
et al., 1998; Bagnasco et al., 2001; Sands, 2002). The first
gene encodes several, alternatively spliced isoforms, named
UT-A1–UT-A6, which are expressed primarily in the renal
tubules, except for UT-A5, which is expressed only in testis
(Smith and Rousselet, 2001). The major renal UT-A isoforms,
UT-A1, UT-A2, and UT-A3, act in concert to concentrate
urea in the renal medulla, thereby negating the osmotic
effects of urea in the urine. This action, together with that
of vasopressin-regulated aquaporins (AQPs), allows water
reabsorption across the medullary collecting ducts and
excretion of hyperosmotic urine (Smith, 2009). In contrast,
the UT-B gene is primarily expressed not only in erythrocytes,
but also in endothelial cells of the kidney and brain (Stewart
et al., 2004). Whether one or more of the above mentioned
UTs are expressed in NHK, the downstream metabolic
consequences of such transport, as well as the potential
clinical relevance of urea transport and uptake into epidermis
are not known.
In this study, we first assessed whether topical urea
enhances epidermal barrier function, and the potential
biochemical basis for such improvement. We then analysed
whether one or more functionally active UTs are expressed
by human keratinocytes. We then determined whether genes
that are involved in skin barrier formation are regulated
by exogenous urea. Specifically, we studied the effects
of exogenous urea on the expression of TG-1, involucrin,
loricrin, and filaggrin, which have important roles in
keratinocyte differentiation, genes encoding for epidermal
lipid and antimicrobial peptide (AMP; i.e., LL-37 and
b-defensin-2) production (Braff and Gallo, 2006). Once
secreted within the extracellular spaces of the stratum
corneum, these AMPs are well localized to inhibit invading
pathogens. Moreover, at least one of these AMP, the
carboxypeptide cleavage product of human cathelicidin
LL-37 is also necessary for normal permeability barrier
function (Aberg et al., 2008), demonstrating the convergence
of these two critical defensive functions (Elias, 2007).
RESULTS
Topical urea enhances human cutaneous permeability barrier
function and AMP expression in normal human skin in vivo
Several anecdotal reports suggest that topical urea could
improve epidermal permeability barrier function. To assess
the impact of urea on cutaneous barrier function, we
conducted a placebo-controlled, double-blinded study of
10 and 20% urea versus placebo applications in 21 healthy
human volunteers. After 4 weeks of once-daily applications,
epidermal barrier function was assessed as changes in
transepidermal water loss (TEWL) on the arms and buttocks,
followed by biopsies for real time PCR and immunohisto-
chemistry from treated and untreated sites on the buttocks.
Basal urea concentration isB150nmol cm2, corresponding
to B125mM, which can be raised from 3.5- to 5-fold upon
application of as little as 2% and 4% urea, respectively
(Gabard and Chatelain, 2003). Although 10% urea did not
significantly alter TEWL, 20% urea significantly improved
skin barrier function, shown as a 31% decrease in TEWL
levels (from 10.0±0.9 to 6.9±0.5 g h1m2; P¼0.003) in
the 21 healthy volunteers (Figure 1a). Biopsies taken at the
end of urea treatments showed that both 10 and 20% urea
significantly enhanced expression of markers for epidermal
antimicrobial defense. Improved barrier function in normal
human volunteers treated with 20% urea was paralleled
by increased mRNA levels for TG-1, involucrin, loricrin,
and filaggrin (Figure 1b), as well as LL-37 and b-defensin-2
(Figure 1c). Nevertheless, although 10% urea treatment also
significantly upregulated the expression of genes involved
in epidermal differentiation and AMP production, it should
be noted that TEWL levels did not significantly improve at
this urea concentration. These studies indicate that topical
applications of 20% urea improve cutaneous barrier function
and expression of antimicrobial defense in normal human
skin.
UT-A1 and A2, as well as AQPs 3, 7, and 9, function
as UTs in keratinocytes
To begin to assess the basis for urea-induced barrier
improvement, we first determined whether urea is taken up
by NHK, and the responsible transporters. As exogenous urea
has been shown to induce the expression of UTs in a variety
of cell types (Smith and Rousselet, 2001; Stewart et al., 2004),
we first assessed basal and urea-induced expression for the
four UTs that have been cloned to date (i.e., the human
isoforms UT-A1, UT-A2, UT-A6, and UT-B (Fenton and
Knepper, 2007)) in NHK under normosmotic (10mM urea)
and hyperosmotic conditions, such as 100mM urea, 192mM
NaCl (Warskulat et al., 2004), and 600mM sorbitol. Expression
levels of UT-A6 and UT-B could only be identified in the
control cell lines HepG2 and caCo-2 (for details see
Supplementary Figure S1c and d online). Both UT-A1 and
UT-A2 are expressed inNHK (Figure 2a), and their expression
increased by 2.9-fold and 2.1-fold under normosmotic
conditions, respectively, comparable to changes in the
physiological ranges that occur in human serum (1–10mM;
Wu, 2006). The extent of upregulation of UT-A1 and UT-A2
at 10mM was similar to those observed in non-keratinocyte
cell lines. Finally, the subsequent decline in UT-A1 and UT-
A2 expression to background levels after treatment with
100mM urea for 24 hours in NHK was not due to cell death
because viability was not affected despite an increased
osmolarity increased (i.e., to 400mosmol l1; for details see
Supplementary Figure S1a and b online).
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One or both UTs is (are) functional, because NHK took up
14C-labeled urea in a manner that could be signifi-
cantly inhibited by coapplications of either phloretin or the
pore-blocking analog, thiourea (Figure 2b), which also
inhibited facilitated transport of urea in kidney, liver, and
red blood cells (Chou and Knepper, 1989; Inoue et al, 2004;
Zhao et al, 2007; Figure 2b). Since neither phloretin nor
thiourea completely blocked urea transport, we next assessed
whether AQPs, which are known to transport small mole-
cules, such as glycerol (Rojek et al., 2008), also transport
urea. Both AQP-3 and -9 are expressed in the differentiating
layers of human epidermal skin equivalents (Sugiyama et al.,
2001) and AQP-7 localizes to superficial epithelial cells
of the gastrointestinal tract (Laforenza et al., 2005). Yet, all
3 AQPs, including AQP-7, are expressed in NHK after
stimulation with relatively low doses of exogenous urea (i.e.,
1–10mM; Figure 2c). By binding to cysteine residues (Cys11 in
human AQP-3), mercury inhibits water and glycerol transport
by mammalian AQPs (Kuwahara et al, 1997), and both nickel
and copper cations inhibit glycerol permeability in human
lung epithelial cells by interference with the extracellular
amino acids Trp128, Ser152, and His241 (Zelenina et al, 2003,
2004). Accordingly, all three of these divalent cations also
significantly inhibited 14C-labeled urea uptake into NHK
(Figure 2d), indicating that AQPs also contribute to the net
uptake of urea by NHK. As urea transport in Xenopus laevis
oocytes has been described for active cotransporters such
as the low affinity Naþ -glucose cotransporter, the Naþ -
iodide cotransporter, and the NaþCl-GABA cotransporter
(Leung et al., 2000) in the absence of their proper substrates,
we also tested urea-inducible expression of these cotranspor-
ters after urea applications in NHK (Figure 2e). Leung and
coworkers (2000) presented evidence that urea transport by
Naþ -glucose cotransporter is not inhibited by urea analogs,
such as thiourea. We then studied inhibition of urea transport
of 34% by the UT-inhibitor, thiourea (Figure 2b), and 66%
by the AQP inhibitor, HgCl2 (Figure 2d). Finally, determina-
tion of copy numbers yielded the highest copy numbers for
UT-A2 (62±9 SE copiesml1), followed by AQP-3 (32±4 SE
copiesml1) and UT-A1 (19±4 SE copies ml1), whereas copy
numbers for Naþ -glucose cotransporter, Naþ -iodide cotran-
sporter, and NaþCl-GABA cotransporter were found to be
as low as 7±1.2 SE, 6±1.4 SE, and 2±0.4 SE, respectively,
indicating only a minor relevance by these cotransporters
(Figure 2f) (for further details see also Supplementary
Figure S2a–c online).
Urea upregulates mRNA expression of differentiation
markers, lipid synthetic enzymes, and AMP
We next assessed the basis for the benefits of urea for
permeability barrier function and antimicrobial defense in
normal epidermis. At the gene level, skin barrier function
actively depends on two parallel processes, i.e., keratinocyte
differentiation, which generates the corneocytes that contribute
to barrier function by several mechanisms (Elias, 2007), and
epidermal lipid synthesis, which generates the extracellular
lamellar bilayers (Elias, 2005) as well as generation of tight
junction proteins (Furuse et al., 2002). Keratinocyte differentia-
tion is orchestrated by regulation of a number of genes (Eckert
and Welter, 1996), including involucrin, filaggrin, loricrin, and
TG-1 (Chen et al., 1995). While TG-1 mRNA levels did not
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Figure 1. In vivo effect of urea treatments on barrier function of normal
human volunteers. (a) Twenty-one normal volunteers were treated once daily
for 4 weeks at three different areas of the left forearm (placebo), the right
forearm (10% urea), and the right upper arm (20% urea). Skin barrier function
was measured as transepidermal water loss (TEWL). Upregulation of (b) skin
differentiation markers and (c) antimicrobial peptide was also assessed in
biopsies taken from buttocks of the same 21 volunteers with normal skin after
treatment once daily over a period of 4 weeks receiving either no treatment
(untreated), or placebo with 0, 10, or 20% urea. Gene expression is
normalized to 18S rRNA. All data represent mean±SE. Statistical significance
was tested by Wilcoxon’s signed-rank test: (a) **Po0.01 before versus
after treatment; (b, c) **Po0.01 versus untreated, þPo0.05, þ þPo0.01
versus placebo. CAMP, human cathelicidin gene.
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change over the initial 24hours of incubation, mRNA levels
increased significantly after exposure of NHK to 5–50mM urea
for 48hours, and at even lower urea doses after 72hours
(Figure 3d). Similar results were observed for both involucrin
and loricrin at 48hours, although filaggrin expression increased
primarily by 72hours of exposure (Figure 3b–d). Specifically,
upregulation of involucrin mRNA (Figure 3b) reached a
1.8-fold±0.1 SE increase after stimulation with 5mM urea for
48hours and a 1.28±9.3SE increase in involucrin protein after
10mM urea treatment for 24hours (Figure 5a). These changes
are comparable to changes in involucrin when keratinocytes
are treated with 1.2mM Ca2þ for 24 or 48hours (Morizane
et al., 2010). By contrast, exogenous urea at 5–10mM did not
upregulate expression of the tight junction protein, claudin-1, at
any of the time points (data not shown).
As noted above, formation of the permeability barrier
requires not only the participation of corneocytes, but also
epidermal lipid synthesis, as well as at least one AMP, i.e.,
the cathelicidin carbocyterminal peptide, LL-37, which is
required not only for antimicrobial defense but also for
permeability barrier function. Accordingly, gene expression
of enzymes involved in lipid synthesis, such as serine
palmitoyl transferase ((SPT)-1/SPT-2), 3-hydroxy-3-methyl-
glutaryl-CoA reductase, and acidic sphingomyelinase increa-
sed after 48 hours of exposure to urea (Figure 3e). Moreover,
urea stimulated mRNA expression of both b-defensin-2 and
cathelicidin in NHK over a wide dose range, and at four time
points assessed (Figure 3f and g). Although the most striking
enhancement by urea on cathelicidin expression occurred
even at low concentrations, b-defensin-2 levels increased
mainly after exposure to X20mM urea for 72–96 hours.
We next confirmed these mRNA results at the protein and
lipid level. Immunohistochemical analyses revealed that
expression of TG-1, loricrin, involucrin, filaggrin, LL-37,
and b-defensin-2, as well as lipid content increased after 10%
urea application compared to untreated skin (Figure 4a–g).
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Figure 2. Expression and functionality of urea transporters (UTs) and aquaporins (AQPs) in human keratinocytes. Human keratinocytes express and upregulate
mRNA encoding UTs (a) and AQPs (c). Under the various conditions indicated, functionality of transporters is shown by inhibition of uptake of 14C-labeled urea
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For volunteer no. 17, we observed a 7.2-fold increase of
loricrin on the protein level after 10% urea treatment
corresponding to a 9.1-fold increase on the mRNA level.
Within the volunteers assessed (n¼3), epidermal thickness
did not change significantly (92.5 mm±1.5 SE for untreated
skin, 91.5 mm±1.5 SE for 10% urea, P¼0.647 paired
Student’s t-test). Together, these results indicate that exo-
genous urea not only stimulates urea transport, but also
transcription of genes involved in keratinocyte differentiation,
epidermal lipid synthesis, and AMP production, providing
a mechanistic basis for improved barrier function and
antimicrobial defense.
Urea-induced enhancement of epidermal barrier function
and AMP expression requires urea uptake
We next assessed whether improved barrier function and
AMP expression require prior urea uptake. As we used an
inhibitor approach, we first determined the concentration
ranges of inhibitors that were not toxic to NHK. Urea-induced
upregulation of involucrin, filaggrin, and TG-1 expression, as
demonstrated above is completely inhibited by phloretin
or thiourea (Table 1). Also, a partial but significant inhibition
of urea-induced gene expression was detected following
application of inhibitors for AQPs such as HgCl2 or CuSO4
(Table 1). Western blotting of extracts from urea-treated NHK
in the presence or absence of inhibitors also showed that
urea-induced increase of involucrin protein expression was
significantly inhibited by HgCl2, although phloretin affected
involucrin expression to a lesser extent due to its own
inducing effects on this protein (Figure 5a and b). In addition,
urea-induced expression of filaggrin protein was significantly
diminished by coincubation with either HgCl2 or phloretin
(Figure 5c and d) (Simon et al., 1996). Likewise, expression
of the genes involved in lipid synthesis was largely blocked
by coapplication of the urea transport inhibitors. Although
urea-induced upregulation of SPT-1 was completely inhibited
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www.jidonline.org 1565
S Grether-Beck et al.
Urea Improves Skin Barrier by Gene Regulation
by the UT inhibitors above, SPT-2 and 3-hydroxy-3-methyl-
glutaryl-CoA reductase upregulation were partially diminished
(Table 1). Because the expression of LL-37 and b-defensin-2
occurs relatively late in differentiation, the effects of UT and
AQP blockade on AMP expression were assessed 72hours post
exposure to 5mM urea. In contrast to the complete inhibition of
urea-induced stimulation of differentiation markers by phloretin
and thiourea, the urea-induced stimulation of b-defensin-2 and
LL-37 expression was partially diminished in NHK coincubated
with phloretin, or thiourea (Table 1). In addition, incubation
with AQP inhibitors, HgCl2 or CuSO4, blocked urea-induced
upregulation of AMP to a similar extent (Table 1). Together,
these results indicate that urea transport and uptake is necessary
for the urea-induced stimulation of epidermal differentiation,
lipid synthesis, and AMP expression.
Urea improves barrier function and upregulates AMP in
a mouse atopic dermatitis (AD) model
We asked next whether these newly appreciated character-
istics of urea predict potential clinical utility. For these
studies, we assessed the effects of topical urea in an
established murine model with AD (Man et al., 2008; Hatano
et al., 2009, 2010), a disease that displays abnormalities in
both permeability barrier function and antimicrobial defense.
AD-like dermatosis is generated by repeated hapten (oxazo-
lone (Ox)) challenges (Ox-AD model). We first assessed
whether applications of urea concurrent with hapten
challenges improved epidermal function in Ox-AD mice.
In placebo-treated, Ox-AD mice, repeated Ox challenges
induced the expected decline in AMP expression (Man
et al., 2008). But, cotreatment with 20% urea reverted both
murine cathelin-related antimicrobial peptide and mouse
b-defensin 3 (murine homologs of cathelicidin and human
b-defensin-2, respectively) expression in Ox-AD mice
(Figure 6a and b). Additionally, 10% urea significantly
improved stratum corneum hydration (Figure 6c) and barrier
function, assessed as TEWL levels (Figure 6d). These results
suggest that topical applications of 10 or 20% urea improve
both epidermal function and AMP expression in this AD
model. Epidermal thickness gradually increased by urea
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Figure 4. Increased skin differentiation, lipid content, and antimicrobial peptide expression after application of 10% urea to human skin. Immuno-
cytochemistry shown in cryosections for (a) transglutaminase (TG)-1, (b) loricrin, (c) involucrin, (d) filaggrin, (e) total lipid, (f) LL-37, and (g) b-defensin 2 of three
randomly chosen volunteers. Quantification with Image J resulted in increases of 3.1-fold for TG-1 (volunteer no. 17), 27.2-fold for loricrin (volunteer no. 17),
1.5-fold for filaggrin (volunteer no. 7), 1.7-fold for involucrin (volunteer no. 17), 1.5-fold for lipid content (volunteer no. 7), 2.7-fold for LL-37 (volunteer no.16),
and 1.7-fold for b-defensin-2 (volunteer no. 16) after treatment with 10% urea as compared with the untreated skin area. Bar¼50 mm.
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treatment from 10 mm (only Ox treated) to 12mm with 5%
urea and to 25 mm with 10 and 20% urea.
DISCUSSION
In the present study, we describe the mechanistic basis for the
unexpected, new properties of topical urea. Human epider-
mal keratinocytes appear to take up urea via specific
transport mechanisms including UT-A1, UT-A2, and AQPs
(i.e., 3, 7, and/or 9). Although these conclusions are based
upon inhibitor studies, rather than a gene knock-down
approach, we utilized non-toxic doses of these agents, and
demonstrated comparable effects with several chemically
unrelated molecules. Also, urea uptake is followed by gene
regulatory events, including increased expression of the UTs
mentioned above, and more importantly, of a number of
genes that are critical for cutaneous skin barrier function and
antimicrobial defense. To our knowledge this is previously
unreported that urea, which has previously been relegated to
solely relatively minor role in the skin as an endogenous
moisturizer, probably has much more than a merely passive
role in the maintenance of epidermal homeostasis. In fact,
urea appears to be a highly active small-molecule regulator of
genes that impact keratinocyte differentiation, lipid synthesis,
and AMP production, together leading to improved perme-
ability barrier function and probably to antimicrobial defense
as well.
Although the signaling pathways involved in urea-induced
changes in gene expression are currently not known, urea-
induced gene regulation does not result from osmotic stress,
because they occur under normal osmotic conditions, and
require the presence of specific transporters. The time course
of urea-induced gene expression points to an indirect
mechanism, because significant upregulation of some of
the genes, i.e., loricrin, filaggrin, LL-37, and b-defensin 2, can
only be observed 48–72 hours after urea exposure. One
explanation for the delayed effects of urea might be that urea
activates the non-energy-dependent, sodium-proton exchan-
ger (NHE1), which could contribute to optimal barrier
function by controlling not only intracellular pH (Mauro
et al. 1995) but also acidification of extracellular domains of
the lower stratum corneum. Acidification in turn activates
pH-sensitive enzymes that both form the epidermal perme-
ability barrier and facility desquamation of cells, mainly in
the outer layers of the stratum corneum. Additionally, urea-
induced non-enzymatic carbamylation might also contribute
to delayed gene expression, although the effect of carbamy-
lation on protein modification, assessed for hemoglobin, only
results in a 1.7-fold increase of protein modification, when
urea concentrations were raised from 4.8 to 30mM (Wynckel
et al., 2000). Besides this more indirect effect, urea can
activate transcription, translation of, and trans-activation by
the immediate early gene transcription factor Egr-1, probably
via serum-responsive elements together with adjacent Ets
motifs in physiological doses with regards to the renal
medulla (Cohen et al., 1996). Although further studies with
transporter-knockout animals might be useful, it is possible
that deletion of one transporter could alter the expression of
other transporters, as shown for UT-B deletions in erythro-
cytes, which upregulate UT-A2, AQP-2, and AQP-3, in a
compensatory fashion (Klein et al., 2004). Similarly, UT-B has
been shown to transport water, when AQP-1 is knocked
out in erythrocytes (Yang and Verkman, 2002). Further
studies will be required to clarify the signalling mechanisms
that account for the stimulation of the multiple proteins and
enzymes shown here.
Our results may explain the many anecdotal observations
that patients with perturbed barrier function and increased
susceptibility towards skin infections benefit from topical
urea application (Stu¨ttgen, 1992; Bissonnette et al., 2010).
Accordingly, we showed that urea can prevent development
of abnormal barrier function and reverse the decrease in AMP
expression in a murine AD model. Also, stimulation of AMP
expression could explain in part the clinical observation that
patients with infectious skin diseases, such as onychomyco-
sis, benefit from urea treatment by improving barrier function,
since tinea infections abrogate the barrier (Bonifaz and Ibarra,
2000; Baran and Tosti, 2002). Urea also could be useful for
the treatment of other skin conditions that display both
altered permeability and antimicrobial defense, such as AD.
Accordingly, acute and chronic lesions of AD patients are
characterized by a decreased expression of b-defensin-2 and
LL-37, which probably explains their propensity to be
colonized by Staphylococcus aureus and viral pathogens
(Kim et al., 2007). UVB radiation was recently described to
induce expression of human b-defensin-2 (Glaser et al., 2009)
and the precursor of LL-37, hCAP18 (Mallbris et al., 2005), in
human skin in vivo. Accordingly, suberythemal UVB
also enhances barrier function and murine cathelin-related
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Figure 5. Inhibition of urea transport by phloretin (50 lM) or HgCl2
(150 lM) decreases the expression of epidermal differentiation markers.
Urea-induced (10mM) expression of involucrin (n¼5) (a) or filaggrin (n¼ 3)
(c) was assessed by western blotting of total cell extracts from normal human
keratinocytes treated for 24 or 72 hours, respectively. Quantification (b, d)
of data is given as mean±SE. Paired Student’s t-test was used for statistical
analyses: *Po0.05, **Po0.01 versus untreated or as indicated. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; NS, not significant.
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antimicrobial peptide production in mice (Hong et al., 2008;
Rodriguez-Martin et al., 2011). Barrier function was also
increased after topical application of calcipotriol in healthy
human skin (Weber et al., 2005), and in lesional psoriatic
skin, vitamin D analogs increase LL-37, but decrease
b-defensin-2 expression (Peric et al., 2009).
The present studies add urea to the list of potential
inducers of antimicrobial defense in human skin. Since urea
is a widely used molecule, with a very low toxicity profile,
these observations should prompt further interest in the use
of urea and urea-related molecules as potential stimulators
of skin antimicrobial defense mechanisms.
In addition to antimicrobial defense, the skin of AD
patients also exhibits defective permeability barrier function.
Accordingly, not only involucrin and loricrin mRNA and
protein expression but also lipids such as ceramides are
greatly diminished both in affected and in unaffected skin of
AD patients (Kim et al., 2008), and the current observation
that urea can increase the expression of these differentiation
genes and the lipid synthetic enzymes, e.g., SPT, provides
another rational for the beneficial effects of urea treatment in
this skin disease. Interestingly, among all differentiation
markers studied, filaggrin expression showed the strongest
upregulation after urea treatment. Accordingly filaggrin
expression, which is reduced in a substantial proportion of
AD patients (Weidinger et al., 2006), might be improved by
topical applications of urea to the skin of heterozygous null
allele carriers (Sandilands et al., 2006; Sergeant et al., 2009).
MATERIALS AND METHODS
Volunteers
Approval had been obtained from the Ethics Committee of the
Heinrich-Heine University. The double-blind, placebo-controlled
study was conducted according to the ethical rules stated in the
Declaration of Helsinki Principles and the ICH GCP guideline was
observed insofar as applicable. Twenty-one healthy human volun-
teers (seven female and fourteen male) were enrolled after written
informed consent. Their age ranged from 21 to 59 years with a mean
Table 1. Effect of inhibitors for UTs (thiourea 100mM and phloretin 50 lM) and AQPs (HgCl2 30 lM, and CuSO4
50 lM) on urea-induced expression of markers involved in epidermal skin barrier formation at time points indicated
Gene Expression in %
Inhibition of UT Inhibition of AQP
Marker Time (h) Concentration of urea (mM) Urea +Thiourea +Phloretin +HgCl2 +CuSO4
Transglut-1 48 5 100±8 0±0* 0±5* 17±2* 29±4*
Involurin 48 5 100±2 0±8** 0±15** 45±6** 22±5**
Filaggrin 48 5 100±5 0±11* 0±11* 42±6** 17±4**
Loricrin 48 5 100±0.6 0±0* 0±8** 39±4** 17±6**
Transglut-1 48 50 100±3 0±17* 0±14* ND ND
Involucrin 48 50 100±3 0±5** 0±5** ND ND
Filaggrin 48 50 100±9 5±5* 0±10* ND ND
Loricrin 48 50 100±3 0±8** 0±0** ND ND
Transglut-1 48 100 100±14 0±0* 0±0* ND ND
Involucrin 48 100 100±12 0±0* 0±9* ND ND
Filaggrin 48 100 100±14 0±12* 0±25* ND ND
Loricrin 48 100 100±10 0±14** 0±0* ND ND
SPT-1 48 5 100±2 0±6** 0±6* 00±6** 67±8NS
SPT-2 48 5 100±2 31±2** 0±3** 9±7** 48±2**
HMGCoAR 48 5 100±3 62±2* 40±2* 28±6* 51±6*
BD2 72 5 100±0.9 46±14** 54±7** 49±4* 39±4**
CAMP 72 5 100±0.9 51±0.9** 28±17** 60±0** 40±5*
BD2 72 10 100±6 ND ND 52±0NS 55±4NS
CAMP 72 10 100±2 ND ND 32±0** 51±2**
Abbreviations: AQP, aquaporin; BD2, b-defensin 2; CAMP, human cathelicidin gene; HMGCoAR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; ND, not
detected; NS, not significant; SPT, serine palmitoyl transferase; Transglut-1, transglutaminase-1; UT, urea transporters.
Given is the gene expression based on 18S rRNA. Gene expression under urea treatment for the indicated markers was set 100%, and the effect of inhibitors
is given as the remaining gene expression.
Paired Student’s t-test versus urea treatment. *Po0.05, **Po0.01.
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age of 40±2.7 SE years, and all individuals were non-smokers and
had no history of any skin disease.
Topical treatment
The volunteers were requested not to use any topical preparations for
at least 2 weeks before the study. Urea was used in concentrations of
either 0, 10, or 20% in a placebo, prepared and provided by ISDIN
(Barcelona, Spain), containing isopropyl myristate, paraffin, glyceryl
stearate, PEG-40 stearate, sorbitol, cetearyl ethylhexanoate, cetyl
alcohol, dimethicone, Persea Gratissima, stearic acid, sodium
carbomer, acrylates, allantoin, methylparaben, propylparaben, lactic
acid, parfum, and 2-bromo-2-nitropropane-1,3 diol in water. For
skin physiological assessments, volunteers were treated once daily
for 4 weeks at three different 4 cm 4 cm areas on the left inner
forearm (placebo), the right inner forearm (10% urea), and the right
upper arm (20% urea). In parallel, three different 4 cm 4 cm large
skin areas on the buttocks were treated identically to obtain 4mm
punch biopsies (Grether-Beck et al., 2008a), which were cut in
halves for either RNA isolation or immunohistochemical staining.
Assessment of permeability barrier function
TEWL levels were measured before and after applications of the
treatments with an evaporimeter (Tewameter TM300, Courage and
Khazaka Electronic GmbH, Cologne, Germany), according to the
guidelines provided by the European Society of Contact Dermatitis
(Pinnagoda et al., 1990). The inner forearms and upper arms
have been chosen as treatment locations, because intra- and inter-
individual variation coefficients are reasonably small. The results
were expressed as DTEWL¼ TEWLaftertreatment–TEWLbeforetreatment in
mgh1m2±SE.
Cells and cell culture
Primary human epidermal keratinocytes (NHK) were prepared from
neonatal foreskin and maintained in culture under serum-free
conditions as described previously (Grether-Beck et al., 2008a).
For induction of differentiation, NHK were seeded and grown up to
confluence. Urea (diaminomethanal, carbamide) was obtained from
ISDIN (Barcelona, Spain). See the Methods section and Supple-
mentary Figure S1(a) and (b) online in the Supplementary material
online at http:/www.nature.com/jid for further details on cell
viability and osmolarity.
RNA isolation and PCR
Total RNA was extracted from cell culture dishes or from frozen
biopsies and gene expression measured by a two-step reverse
transcription real time PCR as described (Grether-Beck et al.,
2008a, b). The primer sequences are available in supplements
(Supplementary Table S1 online). For comparison of relative
expression in real time PCR untreated control cells/biopsies and
treated cells/biopsies the 2DDC(t) method was used (Livak and
Schmittgen, 2001).
Expression of UTs, AQPs, and cotransporters
The mRNA expression of UTs was assessed using quantitative real
time PCR. See the Methods section and Supplementary Figures S1(c)
and (d) online in Supplementary material online at http:/www.
nature.com/jid for further details on validation of primers in control
cell lines and determination of copy numbers.
Measurement of [14C]-urea transport
To test their function in NHK, expression of the transporters was
induced 16 hours before initiation of radiolabeling by 10mM urea in
the absence of bovine pituitary extract. For radiolabeling, 74 kBq
(2mCi) 14C urea (Hartmann Analytic GmbH, Braunschweig) was
added and the cells were incubated for another 4minutes as
described (Klein et al., 1999). Classical inhibitors (all from Sigma-
Aldrich, Steinheim, Germany) of urea transport (Inoue et al., 2004),
e.g., phloretin (50 mM), and thiourea (100mM), were added together
with 14C urea, whereas mercury (HgCl2, 30, 50, and 150 mM
(Kuwahara et al., 1997)), nickel (NiCl2, 50 and 100mM (Zelenina
et al., 2003)), and copper (CuSO4, 50 and 100 mM (Zelenina et al.,
2004)) to inhibit AQP were preincubated for 24 hours. The urea
influx was stopped simultaneously by three rapid washes with ice-
cold solution containing 150mM NaCl, 1mM CaCl2, 1mM MgCl2,
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Figure 6. Urea increases the expression of antimicrobial peptide,
increases skin hydration, and improves transepidermal water loss (TEWL)
in a mouse atopic dermatitis model. After 10 oxazolone (Ox) challenges
over a period of 3 weeks and coapplication of urea treatment twice
daily, immunocytochemistry was performed in paraffin sections (5 mm) for
(a) murine cathelin-related antimicrobial peptide (mCramp) and (b) mouse
b-defensin 3 (mBD3) as compared with a sample with 10 OX challenges
alone (untreated with regard to urea or placebo). Bar¼ 40 mm. (c) Skin
hydration was measured by corneometry and (d) skin barrier function as
TEWL in groups of eight animals each. The dotted line represents the
dermo-epidermal junction. D, dermis.
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and 0.05mM phloretin using a centrifuge. Supernatants and dried
cell pellets were harvested separately. Cell pellets were solubilized
in 0.5ml of 25mM NaOH with 0.5% deoxycholate, 100 ml from each
well was used to measure the protein content with the BCA assay
(Pierce, Rockford, IL), and 500ml was used to count the cells by a
standard scintillation procedure (Beckman Coulter LS 6000IC,
Beckman Coulter GmbH, Krefeld, Germany) using CytoScint ES
(ICN, Irvine, CA) as scintillation fluid. Transport was calculated as
Bq per mg protein (nmol urea per mg protein) and set as 100% for
urea-stimulated cells.
Western blotting
Confluent NHK were stimulated with urea and/or the inhibitor and
cultivated for 24 or 72 hours. The cells were lysed in a buffer
composed of 60mM Tris-HCl (pH 7.8), 150mM NaCl, 5mM EDTA,
10% glycerol, and 60mM n-octyl-b-D glucopyranoside. In all, 10mg
of the lysates for involucrin and 50 ml lysate in Laemmli final sample
buffer for filaggrin were resolved by SDS-Page and immuno-
blotted on nitrocellulose membrane (Trans-blot; Bio-Rad, Munich,
Germany). Antibodies were obtained from Santa Cruz (Santa Cruz,
CA): rabbit polyclonal antibody against human involucrin (H-120,
1:250) and a rabbit polyclonal antibody against human filaggrin
(H-300). GAPDH (Millipore, Temecula, CA) or a-tubulin (Abcam,
Cambridge, UK) served as loading control. The blots were visualized
with the SuperSignal West Pico detection system (Pierce, Rockford,
IL), and were scanned and quantified using spot denso function
from AlphaEase FluorChem 8900, Version 3.2.3 (Alpha Innotech,
San Leandro, CA).
Immunohistochemical staining
Acetone-fixed frozen sections (6mm) were stained with the following
primary antibodies overnight at 41C: from Abcam (Cambridge, UK)
polyclonal rabbit anti human filaggrin antibody (1:1,000), polyclonal
mouse anti loricrin antibody (1:500), monoclonal mouse anti
involucrin antibody (1:200), and monoclonal mouse anti-TG-1
antibody (1:20); from Santa Cruz (Santa Cruz, CA) polyclonal rabbit
anti human LL-37 antibody (1:500) and polyclonal rabbit anti human
b-defensin 2 antibody (1:500). After rinsing in phosphate-buffered
saline, the sections were visualized using a Vectastain ABC-AP kit
(Axxora, Lo¨rrach, Germany). Total lipid staining using Nile Red from
Sigma-Aldrich (Steinheim, Germany) was performed in frozen
sections as described, (Gunathilake et al., 2009) and examined with
an Olympus BX60 fluorescence microscope (Olympus Imaging
Europe GmbH, Hamburg, Germany). The entire field of each section
was examined at  400 magnification. For quantification of
fluorescence intensity, ImageJ software (1.41; US National Institutes
of Health, Bethesda, MD, http://imagej.nih.gov/ij/, 1997–2011) was
used. In detail, the images were saved as tif files, the ratio of stained
areas versus background areas was calculated for each file, setting
this ratio to 1 for untreated skin samples. Epidermal thickness was
measured using ImageJ software. For each treatment (urea or
untreated), ten different sites on three different skin sections were
measured and the mean epidermal thickness was calculated.
Mouse AD model
Female hairless mice (hour/hour) aged 6–8 weeks were purchased
from Charles River Laboratories (Wilmington, MA) and were fed a
standard mouse diet (Ralston-Purina, St Louis, MO) and water ad
libitum. All animal procedures were approved by the Animal Studies
Subcommittee of the San Francisco Veterans Administration Medical
Center and performed in accordance with their guidelines.
Animals were sensitized with a single topical application of
1% Ox (50 ml) to the flank. One week after sensitization, hairless
mice were treated topically with 60 ml of 0.1% Ox on both flanks
once every other day for an additional period of 3 weeks (totally,
10 challenges over 20–21 days) (Man et al., 2008). These mice with
an AD-like dermatosis were divided into four groups (eight animals
each) at the beginning of challenges, and were treated with
placebo containing 0%, 5, 10, or 20% urea. The placebo (Cetaphil,
Galderma, Du¨sseldorf, Germany) cream contains water, petrolatum,
glyceryl polymethacrylate, dicaprylyl ether, glycerol, dimethicone,
glyceryl stearate, cetyl alcohol, Prunus amygdalus dulcis
(sweet almond) oil, PEG-30 glyceryl stearate, tocopheryl acetate,
benzyl alcohol, phenoxyethanol, sodium hydroxide, acrylates/
C10-30 alkyl acrylate crosspolymer, dimethiconol, disodium EDTA,
and propylene glycol. Treatments were applied twice daily at an
interval of 6 hours, and at least 1 hour after prior Ox treatments. Both
before challenges and at the end of the treatment periods, TEWL was
measured with an electrolytic water analyzer (Meeco, Warrington,
PA) and stratum corneum hydration was assessed as capacitance,
with a Corneometer CM820 (Courage & Khazaka, Cologne,
Germany).
Full-thickness skin specimens were fixed in 10% formaldehyde
and embedded in paraffin. Sections (5mm) were cut and immuno-
stained for mouse b-defensin 3 and murine cathelin-related
antimicrobial peptide (primary antibodies from Santa Cruz (Santa
Cruz, CA)). After deparaffinization, sections were rehydrated
sequentially with 100%, 90%, and 70% ethanol and incubated for
15minutes in Tris-buffered saline to inactivate endogenous peroxi-
dases. Samples then were treated for 10minutes with a blocking
serum solution and incubated overnight at 41C with the primary
antibody (1:100 dilution). After several washes in Tris-buffered
saline, they were incubated for 40minutes with a secondary
antibody, FITC-conjugated goat anti-rabbit (Alpha Diagnostics, San
Antonio, TX) at room temperature. Slides were counterstained with
propidium iodide for nuclear visualization, and examined on a Leica
TCS-SP laser confocal microscope (Leica Microsystems, Buffalo
Grove, IL). The thickness of epidermis in mice was measured in three
confocal pictures for each therapy and the ox-treated animals (three
different measures each) using NIS-Elements 3.0 (Nikon Instruments,
Melville, NY).
Statistical analyses
NHK cell culture experiments were performed in three independent
experiments with cells derived from three different donors. Data
shown in each figure are from experiments performed in one
representative individual in triplicate, unless otherwise indicated.
Data are presented as mean±SE. Student’s t-test or Wilcoxon signed
rank test was used for comparison between two groups, Po0.05 was
considered significant.
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